Gastritis Treatment Market Research Report – Forecast to 2027

Gastritis Treatment Market Information: By Diagnosis (Blood Test and Endoscopy), Treatment (Acid Blocking Medicines and Antibiotics), Drug Distribution Channel (Retail Pharmacy), and End-User (Hospitals and Clinics) - Forecast Till 2027

ID: MRFR/Pharma/4769-HCR | February 2021 | Region: Global | 90 pages

Gastritis Treatment Market Scenario


The gastritis treatment market is expected to exhibit a robust growth rate during the forecast period. Gastritis is characterized by a set of conditions that cause inflammation or irritation of the lining of the stomach, for a short or long time. Upper abdominal pain or discomfort is the most common symptom of Gastritis.  Gastritis has been broadly categorized into three segments, namely, acute gastritis, chronic gastritis, and erosion of metaplasia or atrophic gastritis. The market for gastritis treatment is expanding worldwide due to drivers such as increasing occurrence of acute and chronic gastritis, advances in the area of medical technologies, increasing fast food chains worldwide, massive adoption of a sedentary lifestyle, and advancement in endoscopy devices that increased the accuracy of diagnosis. Moreover, chronic gastritis patients, rely on acidity reducing medicines for a lifetime, thus fueling the market demand which in turn would boost up the market growth. However, unaffordability and lack of advanced medical device technology in middle-income countries are likely to hamper the gastritis treatment market growth.


Research Methodology:


 Gastritis Treatment Market


Source: World Health Organization, Centers for Disease Control and Prevention, American Heart Association, National Institute of Health, American College of Cardiology, European Heart Network, expert interview, annual report, white paper, company presentation and market research future analysis


Market Players



  • Abbott Laboratories

  • AstraZeneca PLC

  • Novartis AG

  • Microbiotix, Inc

  • Reddy’s Laboratories

  • Lupin Ltd

  • Perrigo Pharmaceutical

  • Cipla Inc.

  • Pfizer Inc.

  • SUN Pharmaceuticals Industries limited


Market Segmentation                                                                                                                          


The gastritis treatment market is segmented on the basis of diagnosis, treatment type, drug distribution channel, and end-users.


Considering the diagnosis, the market is segmented into blood test, endoscopy, x-ray of the upper digestive system and others.


By treatment type, the gastritis treatment market is segmented into acid-blocking medicines, antibiotics, antacids, and histamine blockers.


With reference to the drug distribution channel, the gastritis treatment market is segmented into retail pharmacy, online pharmacy, and hospital pharmacy.


On account of end-users, the gastritis treatment market is segmented hospitals & clinics and others.


Based on region the market is segmented into Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.


Regional Market Summary


The Americas is going to account for the largest share for gastritis treatment market. Drivers such as widespread of fast food chains in this region along with the increasing sedentary life culture which in turn contributes to increasing patient pool of gastritis and rising geriatric population are likely to enhance the growth of gastritis treatment market. Moreover, rising alcohol abuse, the presence of prominent key players is likely to spur the market growth.  For instance, According to a published survey, approximately 1 in 100 is a victim of gastritis in the US. Thus, this increasing patient pool will enhance the market growth during the forecasted period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and availability of favorable reimbursement policies are likely to propel the growth of gastritis treatment market in the American region. Furthermore, according to CMS (Centers for Medicare and Medicaid Services) US health care spending increased 4.3 percent to reach USD 3.3 trillion per person in 2016. Thus, the increasing per capita income of individuals, as well as rising healthcare spending, will aid up the market growth of the Americas.


Europe is the second market leader and holds a healthy share in the gastritis treatment market. The European market is expected to exhibit a sturdy growth rate during the forecast period owing to the availability of advanced treatment facilities, established healthcare infrastructure along with the presence of a flourishing medical device market which helps in efficient and accurate diagnosis. Furthermore, due to the increasing number of lactose-intolerant issues, vulnerability to falling prey of gastritis is more likely to lead to an increasing number of gastritis sufferers. Thus, fueling the market growth during the forecast period.


Asia-Pacific is expected to be the fastest emerging market owing to increasing government initiatives for healthcare reform, increasing adaption of a sedentary lifestyle, and increasing prevalence of gastritis. Moreover, the prevalence of multifocal atrophic gastritis and gastric adenocarcinomas is high in these regions. Furthermore, the presence of renowned domestic pharmaceutical players, as well as the increasing healthcare spending per capita, is going to accelerate the market growth during the forecast period.


The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers. With an increasing number of gastrointestinal disorders region in this region, many key players are willing to set up their research and development centers to find a cure for these diseases. Moreover, the government is aiming at improving the healthcare infrastructure. Thus, a steady growth rate might be seen during the forecast period.


Gastritis Treatment Market Share (%), by Region, 2017


 Gastritis Treatment Market Share


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis


Market Segmentation & Key players


Gastritis Treatment Market, by Diagnosis         



  • Blood test

  • Endoscopy

  • X-ray of upper digestive system

  • Others


Gastritis Treatment Market, by Treatment type



  • Acid-blocking medicines

  • Antibiotics

  • Antacids

  • Histamine Blockers


Gastritis Treatment Market, by Drug Distribution Channel



  • Retail Pharmacy

  • Online Pharmacy

  • Hospital Pharmacy


Gastritis Treatment Market, by End-User



  • Hospital & Clinics

  • Others


Gastritis treatment Market, By Region


North America



  • US

  • Canada


South America


Europe



  • Western Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia-Pacific


Middle East and Africa



  • United Arab Emirates

  • Saudi Arabia

  • Oman

  • Kuwait

  • Qatar

  • Rest of the Middle East & Africa       


Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2020-2027: Substantial CAGR
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, Drug Distribution, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott Laboratories, AstraZeneca PLC, Novartis AG, Microbiotix, Inc, Reddy’s Laboratories, Lupin Ltd, Perrigo Pharmaceutical, Cipla Inc., Pfizer Inc., SUN Pharmaceuticals Industries limited
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing occurrence of acute and chronic gastritis
  • Advances in the area of medical technologies
  • Increasing fast food chains worldwide
  • Massive adoption of a sedentary lifestyle
  • Advancement in endoscopy devices that increased the accuracy of diagnosis


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The Americas is expected to lead the Gastritis Treatment Market.

    Rising prevalence of chronic gastritis and advancement in endoscopy devices are adding market growth.

    Hospitals and clinics are the end users of gastritis treatment.

    Top players in the Gastritis Treatment Market include SUN Pharmaceuticals Industries Limited, Pfizer Inc., Cipla Inc., Perrigo Pharmaceutical, Lupin Ltd, Dr. Reddy’s Laboratories, Microbiotix, Inc, Novartis AG, AstraZeneca PLC, and Abbott Laboratories.

    Different strategies used by market players to create a dominance in the Gastritis Treatment Market include acquisitions, product launches, partnerships, and collaborations.

    Table of Content

    1. Report Prologue

    2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    6. Global Gastritis Treatment Market, by Diagnosis

    6.1 Introduction

    6.2 Blood test

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    6.3 Endoscopy

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    6.4 X-ray of the upper digestive system

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    6.3 Others

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    7. Global Gastritis Treatment Market, by Treatment type

    7.1 Introduction

    7.2 Acid-blocking medicines

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    7.3 Antibiotics

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    7.4 Antacids

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    7.4 Histamine Blockers

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    8. Global Gastritis Treatment Market, by Drug Distribution Channel

    8.1 Introduction

    8.2 Retail Pharmacy

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    8.3 Online Pharmacy

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    8.3 Hospital Pharmacy

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    9. Global Gastritis Treatment Market, by End-User

    9.1 Introduction

    9.2 Hospital & Clinics

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    9.3 Others

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    10 Global Gastritis Treatment Market, by Region

    10.1 Introduction

    10.2 Americas

    • Market Estimates & Forecast, by Region, 2020–2027

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.2.1 North America

    • Market Estimates & Forecast, by Country, 2020–2027

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.2.1.1 US

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.2.1.2 Canada

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.2.2 South America

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3 Europe

    • Market Estimates & Forecast, by Region, 2020–2027

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1 Western Europe

    • Market Estimates & Forecast, by Country, 2020–2027

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.1 Germany

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.2 France

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.3 UK

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.4 Italy

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.5 Spain

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.6 Rest of Western Europe

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.2 Eastern Europe

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4 Asia-Pacific

    • Market Estimates & Forecast, by Country, 2020–2027

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.1 Japan

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.2 China

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.3 India

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.4 Australia

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.5 Republic of Korea

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.6 Rest of Asia-Pacific

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5 The Middle East & Africa

    • Market Estimates & Forecast, by Region, 2020–2027

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.1 United Arab Emirates

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.2 Saudi Arabia

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.3 Oman

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.4 Kuwait

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.5 Qatar

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.6 Rest of the Middle East & Africa

    • Market Estimates & Forecast, by Diagnosis , 2020–2027

    • Market Estimates & Forecast, by Treatment type, 2020–2027

    • Market Estimates & Forecast, by Drug Distribution Channel, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    12 Company Profiles

    12.1 AstraZeneca PLC

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 Novartis AG.

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 SUN Pharmaceuticals limited

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Microbiotix, Inc

    12.4.1 Company Overview

    12.4.2 Product

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Dr. Reddy’s Laboratories

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 Lupin Ltd

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 Perrigo Pharmaceutical

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Cipla Inc.

    12.8.1 Overview

    12.8.2 Product Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Abbott Laboratories

    12.9.1 Overview

    12.9.2 Product Overview

    12.9.3 Financials

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 Pfizer Inc.

    12.10.1 Overview

    12.10.2 Product Overview

    12.10.3 Financials

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of the Pharmaceutical Industry

    14 Appendix

    LIST OF TABLES

    Table 1 Gastritis Treatment Industry Synopsis, 2020–2027

    Table 2 Global Gastritis Treatment Market Estimates and Forecast, 2020–2027, (USD Million)

    Table 3 Global Gastritis Treatment Market, by Region, 2020–2027, (USD Million)

    Table 4 Global Gastritis Treatment Market, by Treatment type, 2020–2027, (USD Million)

    Table 5 Global Gastritis Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 6 Global Gastritis Treatment Market, by Drug Distribution Channel, 2020–2027, (USD Million)

    Table 7 Global Gastritis Treatment Market, by End-Users, 2020–2027, (USD Million)

    Table 8 North America Gastritis Treatment Market, by Treatment type, 2020–2027, (USD Million)

    Table 9 North America Gastritis Treatment Market, by Drug Distribution Channel, 2020–2027, (USD Million)

    Table 10 North America Gastritis Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 11 North America Gastritis Treatment Market, by End-Users, 2020–2027, (USD Million)

    Table 12 US Gastritis Treatment Market, by Treatment type, 2020–2027, (USD Million)

    Table 13 US Gastritis Treatment Market, by Drug Distribution Channel, 2020–2027, (USD Million)

    Table 14 US Gastritis Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 15 US Gastritis Treatment Market, by End-Users, 2020–2027, (USD Million)

    Table 16 Canada Gastritis Treatment Market, by Treatment type, 2020–2027, (USD Million)

    Table 17 Canada Gastritis Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 18 Canada Gastritis Treatment Market, by Drug Distribution Channel, 2020–2027, (USD Million)

    Table 19 Canada Gastritis Treatment Market, by End-Users, 2020–2027, (USD Million)

    Table 20 South America Gastritis Treatment Market, by Treatment type, 2020–2027, (USD Million)

    Table 21 South America Gastritis Treatment Market, by Drug Distribution Channel, 2020–2027, (USD Million)

    Table 22 South America Gastritis Treatment Market, by End-Users, 2020–2027, (USD Million)

    Table 23 Europe Gastritis Treatment Market, by Treatment type, 2020–2027, (USD Million)

    Table 24 Europe Gastritis Treatment Market, by Drug Distribution Channel, 2020–2027, (USD Million)

    Table 25 Europe Gastritis Treatment Market, by End-Users, 2020–2027, (USD Million)

    Table 26 Western Europe Gastritis Treatment Market, by Treatment type, 2020–2027, (USD Million)

    Table 27 Western Europe Gastritis Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 28 Western Europe Gastritis Treatment Market, by Drug Distribution Channel, 2020–2027, (USD Million)

    Table 29 Western Europe Gastritis Treatment Market, by End-Users, 2020–2027, (USD Million)

    Table 30 Eastern Europe Gastritis Treatment Market, by Treatment type, 2020–2027, (USD Million)

    Table 31 Eastern Europe Gastritis Treatment Market, by Treatment type, 2020–2027, (USD Million)

    Table 32 Eastern Europe Gastritis Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 33 Eastern Europe Gastritis Treatment Market, by Drug Distribution Channel, 2020–2027, (USD Million)

    Table 34 Eastern Europe Gastritis Treatment Market, by End-Users, 2020–2027, (USD Million)

    Table 35 Asia-Pacific Gastritis Treatment Market, by Treatment type, 2020–2027, (USD Million)

    Table 36 Asia-Pacific Gastritis Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 37 Asia-Pacific Gastritis Treatment Market, by Drug Distribution Channel, 2020–2027, (USD Million)

    Table 38 Asia-Pacific Gastritis Treatment Market, by End-Users, 2020–2027, (USD Million)

    Table 39 Middle East & Africa Gastritis Treatment Market, by Treatment type, 2020–2027, (USD Million)

    Table 40 Middle East & Africa Gastritis Treatment Market, by Drug Distribution Channel, 2020–2027, (USD Million)

    Table 41 Middle East & Africa Gastritis Treatment Market, by End-Users, 2020–2027, (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Gastritis Treatment Market

    Figure 3 Segmentation Market Dynamics for Gastritis Treatment Market

    Figure 4 Global Gastritis Treatment Market Share, by Treatment type 2020

    Figure 5 Global Gastritis Treatment Market Share, by Diagnosis 2020

    Figure 6 Global Gastritis Treatment Market Share, by End-Users, 2020

    Figure 7 Global Gastritis Treatment Market Share, by Region, 2020

    Figure 8 North America Gastritis Treatment Market Share, by Country, 2020

    Figure 9 Europe Gastritis Treatment Market Share, by Country, 2020

    Figure 10 Asia-Pacific Gastritis Treatment Market Share, by Country, 2020

    Figure 11 Middle East & Africa Gastritis Treatment Market Share, by Country, 2020

    Figure 12 Global Gastritis Treatment Market: Company Share Analysis, 2020 (%)

    Figure 13 AstraZeneca PLC: Key Financials

    Figure 14 AstraZeneca PLC: Segmental Revenue

    Figure 16 AstraZeneca PLC: Geographical Revenue

    Figure 17 Lupin Ltd: Key Financials

    Figure 18 Lupin Ltd: Segmental Revenue

    Figure 19 Lupin Ltd: Geographical Revenue

    Figure 20 Perrigo Pharmaceutical: Key Financials

    Figure 21 Perrigo Pharmaceutical: Segmental Revenue

    Figure 22 Perrigo Pharmaceutical: Geographical Revenue

    Figure 23 Pfizer Inc.: Key Financials

    Figure 24 Pfizer Inc.: Segmental Revenue

    Figure 25 Pfizer Inc.: Geographical Revenue

    Figure 26 Pfizer Inc.: Key Financials

    Figure 27 Abbott Laboratories: segmental revenue

    Figure 28 Abbott Laboratories. Geographical revenue

    Figure 29 Novartis AG.: key financials

    Figure 30 Novartis AG: segmental revenue

    Figure 31 Novartis AG: geographical revenue